TKNO Q1 2023 Earnings — Alpha Teknova, Inc. Revenue & Financial Results | Market Cap Arena

TKNOAlpha Teknova, Inc.

$133M

Q1 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$9M-18.2% YoY

Gross Profit

$2M26.6% margin

Operating Income

-$9M-98.1% margin

Net Income

-$9M-96.7% margin

EPS (Diluted)

$-0.31

QoQ Revenue Growth

+15.6%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$12M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$141M

Total Liabilities

$49M

Stockholders' Equity

$92M

Cash & Equivalents

$30M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$11M	-18.2%
Gross Profit	$2M	$5M	-54.7%
Operating Income	-$9M	-$6M	-53.1%
Net Income	-$9M	-$5M	-60.4%

Revenue Segments

Lab Essentials

$7M80%

Clinical Solutions

$2M18%

Other Product

$255,0003%

Geographic Segments

UNITED STATES

$9M96%

Non-US

$395,0004%